Library — CHDR

Search

Filter

Clinical validation of digital biomarkers for paediatric patients with asthma and cystic fibrosis: potential for clinical trials and clinical care.

Kruizinga MD, Essers E, Stuurman FE, Yavuz Y, de Kam ML, Zhuparris A, Janssens HM, Groothuis I, Sprij AJ, Nuijsink M, Cohen AF, Driessen GJA

The European respiratory journal, 2022 Jun

View publication
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IM, de Kam ML, Burggraaf J, Cohen AF, Cazzola M, Calzetta L, Singh D, Spina D, Walker MJ, Page CP

The Lancet. Respiratory medicine, 2018 Aug; 1(9):714-27

View publication
Sputum RNA signature in allergic asthmatics following allergen bronchoprovocation test.

Zuiker RG, Tribouley C, Diamant Z, Boot JD, Cohen AF, Van Dyck K, De Lepeleire I, Rivas VM, Malkov VA, Burggraaf J, Ruddy MK

European clinical respiratory journal, 2016 May

View publication
Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy.

van den Blink B, Dillingh MR, Ginns LC, Morrison LD, Moerland M, Wijsenbeek M, Trehu EG, Bartholmai BJ, Burggraaf J

The European respiratory journal, 2016 Feb; 47(3):889-97

View publication
Reproducibility of biomarkers in induced sputum and in serum from chronic smokers.

Zuiker RG, Kamerling IM, Morelli N, Calderon C, Boot JD, de Kam M, Diamant Z, Burggraaf J, Cohen AF

Pulmonary pharmacology & therapeutics, 2015 Jul

View publication
Reversal of opioid-induced respiratory depression by BK-channel blocker GAL021: A pharmacokinetic-pharmacodynamic modeling study in healthy volunteers.

Roozekrans M, Olofsen E, van der Schrier R, van Gerven J, Peng S, McLeod J, Dahan A

Clinical pharmacology and therapeutics, 2015 May; 97(6):641-9

View publication
Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis.

Dillingh MR, van den Blink B, Moerland M, van Dongen MG, Levi M, Kleinjan A, Wijsenbeek MS, Lupher ML, Harper DM, Getsy JA, Hoogsteden HC, Burggraaf J

Pulmonary pharmacology & therapeutics, 2013 Nov; 26(6):672-6

View publication
MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers.

Boot JD, De Haas SL, Van Gerven JM, De Smet M, Leathem T, Wagner J, Denker A, Miller D, Van Doorn MB, Schoemaker RC, Cohen AF, Diamant Z

Pulmonary pharmacology & therapeutics, 2008 Apr; 21(3):573-7

View publication
Nasal nitric oxide: longitudinal reproducibility and the effects of a nasal allergen challenge in patients with allergic rhinitis.

Boot JD, de Kam ML, Mascelli MA, Miller B, van Wijk RG, de Groot H, Cohen AF, Diamant Z

Allergy, 2007 Mar; 62(4):378-84

View publication

«
1
2
»